CliffBio
biologic

Lucentis

ranibizumab

Loss of exclusivityOctober 2028projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameLucentis
Active ingredientranibizumab
Strength10MG/ML (0.5MG/0.05ML)
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalOctober 2016
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lucentis patent cliff — loss of exclusivity October 2028 | CliffBio